JP2024533153A5 - - Google Patents

Info

Publication number
JP2024533153A5
JP2024533153A5 JP2024513893A JP2024513893A JP2024533153A5 JP 2024533153 A5 JP2024533153 A5 JP 2024533153A5 JP 2024513893 A JP2024513893 A JP 2024513893A JP 2024513893 A JP2024513893 A JP 2024513893A JP 2024533153 A5 JP2024533153 A5 JP 2024533153A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
dual agonist
patient
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024513893A
Other languages
English (en)
Japanese (ja)
Other versions
JP7860224B2 (ja
JP2024533153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/074420 external-priority patent/WO2023031380A1/en
Publication of JP2024533153A publication Critical patent/JP2024533153A/ja
Publication of JP2024533153A5 publication Critical patent/JP2024533153A5/ja
Application granted granted Critical
Publication of JP7860224B2 publication Critical patent/JP7860224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024513893A 2021-09-03 2022-09-02 投薬レジーム Active JP7860224B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21194879.9 2021-09-03
EP21194879 2021-09-03
EP22160234.5 2022-03-04
EP22160234 2022-03-04
PCT/EP2022/074420 WO2023031380A1 (en) 2021-09-03 2022-09-02 Dosage regime

Publications (3)

Publication Number Publication Date
JP2024533153A JP2024533153A (ja) 2024-09-12
JP2024533153A5 true JP2024533153A5 (enExample) 2024-10-09
JP7860224B2 JP7860224B2 (ja) 2026-05-15

Family

ID=84272918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513893A Active JP7860224B2 (ja) 2021-09-03 2022-09-02 投薬レジーム

Country Status (11)

Country Link
US (1) US20250073311A1 (enExample)
EP (1) EP4392054A1 (enExample)
JP (1) JP7860224B2 (enExample)
KR (1) KR20240058121A (enExample)
AU (1) AU2022339044A1 (enExample)
CA (1) CA3228429A1 (enExample)
CL (1) CL2024000647A1 (enExample)
IL (1) IL311166A (enExample)
MX (1) MX2024002600A (enExample)
TW (1) TW202315882A (enExample)
WO (1) WO2023031380A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
WO2026052859A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide
WO2026052861A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
AU2017373901B2 (en) 2016-12-09 2021-06-03 Zealand Pharma A/S GLP-1/GLP-2 dual agonists
WO2018104558A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4126003A1 (en) * 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
IL301891A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
AU2021399904B2 (en) * 2020-12-16 2024-09-05 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
TWI921427B (zh) * 2020-12-16 2026-04-11 丹麥商西蘭製藥公司 Glp-1/glp-2雙重促效劑之醫藥組合物

Similar Documents

Publication Publication Date Title
RU2007125259A (ru) Способ и устройство для введения адреналина
JP2004504406A5 (enExample)
RU2011139643A (ru) Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
JP2010525050A5 (enExample)
JP2007515469A5 (enExample)
JP2017061561A (ja) ニタゾキサニドの制御放出医薬配合物
RU2013119938A (ru) Фармацевтическая композиция
MXPA03010731A (es) Combinacion de agonista del receptor a2a de adenosina y tiotropio o sus derivados para tratar enfermedades obstructivas de vias aereas.
TW200528104A (en) Combination therapy for hcv infection
CN1856339A (zh) 肺动脉高血压症治疗的伊洛前列素联合疗法
EP3678643B1 (en) Sublingual epinephrine tablets
JP2006513184A5 (enExample)
JP2017533972A5 (enExample)
CN1512885A (zh) 药物组合
CN101068571A (zh) 改善透粘膜给药制剂的吸收的方法
CN1701793A (zh) 吡非尼酮治疗肝损伤坏死和急性肺损伤的用途
RU2543635C2 (ru) Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
JP2023502053A5 (enExample)
Galanello Iron chelation: new therapies
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
CN1863512A (zh) 控释药物组合物及其制备方法
JP2004506605A5 (enExample)
US7998973B2 (en) Tivozanib and temsirolimus in combination
CN1871011A (zh) Bh4在治疗呼吸系统疾病中的用途